Investors in Akebia Therapeutics (NASDAQ:AKBA) Have Unfortunately Lost 73% Over the Last Five Years

Yahoo Finance12/20 20:27

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire12/04 05:05

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo (Vadadustat) for CKD Patients on Dialysis

PR Newswire12/03 20:00

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

PR Newswire11/25 21:00

Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In...

Benzinga11/14 21:26

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

PRNewswire11/14 21:00